Wall Street analyst estimates for Avalo Therapeutics, Inc. (AVTX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 8 |
| Hold | 1 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 10 |
| Avg rating (1-5) | 0.70 |
Valuation Ratios
| Price / Book | 1.61 |
| EV / EBITDA | -9.25 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $27.8M | $18.3M | $6.8M | $6.7M | $5.4M | $18.1M | $1.9M | $441000 | $59000 |
| Cost of Revenue | $8.2M | $635648 | $7.5M | -$566523 | $300000 | $1.5M | $3.4M | $1.3M | -$366000 | 0 |
| Gross Profit | -$7.1M | $27.2M | $10.8M | $7.3M | $6.4M | $3.9M | $14.6M | $640000 | $807000 | $59000 |
| Research & Development | $10.2M | $4.4M | $5.8M | $11.8M | $32.2M | $59.8M | $31.3M | $13.8M | $52.1M | $50.1M |
| Selling, General & Admin | $7.1M | $8.9M | $19.2M | $11.6M | $19.8M | $24.7M | $20.7M | $10.3M | $17.2M | $22.9M |
| Operating Expenses | $17.2M | $13.3M | $29.5M | $23.5M | $6.4M | $86.0M | $52.1M | $28.0M | $69.3M | $73.0M |
| Operating Income | -$16.1M | $13.9M | -$39.3M | -$16.1M | 0 | -$82.1M | -$37.4M | -$27.4M | -$68.5M | -$72.9M |
| EBITDA | -$16.1M | $14.3M | -$13.1M | -$13.5M | -$45.5M | -$80.5M | -$37.3M | -$23.3M | -$34.8M | -$77.8M |
| Interest Expense | $464181 | $24016 | 0 | 0 | 0 | $2.4M | $4.2M | $3.4M | 0 | 0 |
| Pre-tax Income | -$16.5M | $13.8M | -$40.1M | -$16.0M | -$67.2M | -$84.5M | -$41.6M | -$31.5M | -$35.0M | -$78.1M |
| Income Tax | $364144 | $2.0M | -$33910 | $280316 | -$2.8M | -$196000 | $28000 | $14000 | $114000 | $165000 |
| Net Income | -$16.5M | $11.9M | -$40.1M | -$16.1M | -$63.5M | -$84.4M | -$41.7M | -$31.5M | -$35.1M | -$78.3M |
| EPS | $-21.93 | $1856.88 | $-3317.28 | $-819.74 | $-2523.77 | $-2330.66 | $-1062.65 | $-113.58 | $-4.32 | $-5.84 |
| EPS (Diluted) | $-21.93 | $1822.74 | $-3317.28 | $-819.74 | $-2523.77 | $-2330.66 | $-1062.65 | $-113.58 | $-3.26 | $-5.84 |
| Shares Outstanding (Diluted) | $3066 | $6512 | $12074 | $19849 | $25511 | $36191 | $39202 | $277727 | $10.8M | $13.4M |
Price
| Price | $16.58 |
| Market Cap | $872M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AARD · BDTX · CHRS · CRBU · ENTA · EPRX · IVA
Explore sector: Healthcare · Biotechnology
More sections of AVTX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks